SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Morgan Bradley Paul

(Last) (First) (Middle)
280 EAST GRAND AVENUE

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP Drug Discovery & Early Dev
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2017
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/31/2017 M(1) 16,666 A $6.67 63,107 D
Common Stock 08/31/2017 S(2) 16,666 D $15 46,441 D
Common Stock 08/31/2017 M(1) 15,206 A $7.96 61,647 D
Common Stock 08/31/2017 S(2) 15,206 D $15 46,441 D
Common Stock 08/31/2017 M(1) 2,294 A $7.96 48,735 D
Common Stock 08/31/2017 S(2) 2,294 D $15 46,441 D
Common Stock 08/31/2017 M(1) 11,552 A $9.65 57,993 D
Common Stock 08/31/2017 S(2) 11,552 D $15 46,441 D
Common Stock 08/31/2017 M(1) 13,448 A $9.65 59,889 D
Common Stock 08/31/2017 S(2) 13,448 D $15 46,441 D
Common Stock 08/31/2017 M(1) 3,795 A $6 50,236 D
Common Stock 08/31/2017 S(2) 3,795 D $15 46,441 D
Common Stock 08/31/2017 M(1) 21,204 A $6 67,645 D
Common Stock 08/31/2017 S(2) 21,204 D $15 46,441 D
Common Stock 08/31/2017 M(1) 1,079 A $6.3 47,520 D
Common Stock 08/31/2017 S(2) 1,079 D $15 46,441 D
Common Stock 08/31/2017 M(1) 13,920 A $6.3 60,361 D
Common Stock 08/31/2017 S(2) 13,920 D $15 46,441 D
Common Stock 08/31/2017 M(1) 617 A $9.42 47,058 D
Common Stock 08/31/2017 S(2) 617 D $15 46,441 D
Common Stock 08/31/2017 M(1) 11,883 A $9.42 58,324 D
Common Stock 08/31/2017 S(2) 11,883 D $15 46,441 D
Common Stock 08/31/2017 M(1) 694 A $11.1 47,135 D
Common Stock 08/31/2017 S(2) 694 D $15 46,441 D
Common Stock 08/31/2017 M(1) 2,639 A $11.1 49,080 D
Common Stock 08/31/2017 S(2) 2,639 D $15 46,441 D
Common Stock 08/31/2017 M(1) 695 A $11.1 47,136 D
Common Stock 08/31/2017 S(2) 695 D $15 46,441 D
Common Stock 08/31/2017 M(1) 2,638 A $11.1 49,079 D
Common Stock 08/31/2017 S(2) 2,638 D $15 46,441 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option (right to buy) $6 08/31/2017 M 21,204 04/05/2013 03/05/2023 Common Stock 21,204 $0.0 0 D
Incentive Stock Option (right to buy) $6.3 08/31/2017 M 13,920 04/05/2012 03/05/2022 Common Stock 13,920 $0.0 0 D
Incentive Stock Option (right to buy) $7.96 08/31/2017 M 2,294 03/26/2015 02/26/2025 Common Stock 2,294 $0.0 8,750 D
Incentive Stock Option (right to buy) $9.42 08/31/2017 M 11,883 03/28/2011 02/28/2021 Common Stock 11,883 $0.0 0 D
Incentive Stock Option (right to buy) $9.65 08/31/2017 M 13,448 03/24/2014 02/24/2024 Common Stock 13,448 $0.0 5,000 D
Incentive Stock Option (right to buy) $11.1 08/31/2017 M 2,639 03/26/2009 02/26/2019 Common Stock 2,639 $0.0 2,638 D
Incentive Stock Option (right to buy) $11.1 08/31/2017 M 2,638 03/26/2009 02/26/2019 Common Stock 2,638 $0.0 0 D
Non-Qualified Stock Option (right to buy) $6 08/31/2017 M 3,795 04/05/2013 03/05/2023 Common Stock 3,795 $0.0 0 D
Non-Qualified Stock Option (right to buy) $6.3 08/31/2017 M 1,079 04/05/2012 03/05/2022 Common Stock 1,079 $0.0 0 D
Non-Qualified Stock Option (right to buy) $6.67 08/31/2017 M 16,666 03/23/2016 02/23/2026 Common Stock 16,666 $0.0 14,517 D
Non-Qualified Stock Option (right to buy) $7.96 08/31/2017 M 15,206 03/26/2015 02/26/2025 Common Stock 15,206 $0.0 3,750 D
Non-Qualified Stock Option (right to buy) $9.42 08/31/2017 M 617 03/28/2011 02/28/2021 Common Stock 617 $0.0 0 D
Non-Qualified Stock Option (right to buy) $9.65 08/31/2017 M 11,552 03/24/2014 02/24/2024 Common Stock 11,552 $0.0 0 D
Non-Qualified Stock Option (right to buy) $11.1 08/31/2017 M 694 03/26/2009 02/26/2019 Common Stock 694 $0.0 695 D
Non-Qualified Stock Option (right to buy) $11.1 08/31/2017 M 695 03/26/2009 02/26/2019 Common Stock 695 $0.0 0 D
Explanation of Responses:
1. The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017.
2. The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017.
Bradley Morgan 09/01/2017
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

       The undersigned, as a Section 16 reporting person of 
Cytokinetics, Incorporated (the Company), hereby constitutes and 
appoints Robert I. Blum Ching Jaw and Peter S. Roddy, and each of them, the 
undersigned's true and lawful attorney-in-fact to

1.	complete and execute Forms 3, 4 and 5 and other forms and 
all amendments thereto as such attorney-in-fact shall in 
his or her discretion determine to be required or 
advisable pursuant to Section 16 of the Securities 
Exchange Act of 1934 (as amended) and the rules and 
regulations promulgated thereunder, or any successor laws 
and regulations, as a consequence of the undersigneds 
ownership, acquisition or disposition of securities of 
the Company; and

2.	do all acts necessary in order to file such forms with 
the Securities and Exchange Commission, any securities 
exchange or national association, the Company and such 
other person or agency as the attorney-in-fact shall deem 
appropriate.

       The undersigned hereby ratifies and confirms all that said 
attorneys-in-fact and agents shall do or cause to be done by virtue 
hereof.  The undersigned acknowledges that the foregoing attorneys-
in-fact, in serving in such capacity at the request of the 
undersigned, are not
 assuming, nor is the Company assuming, any of 
the undersigneds responsibilities to comply with Section 16 of the 
Securities Exchange Act of 1934 (as amended).

       This Power of Attorney shall remain in full force and effect 
until the undersigned is no longer required to file Forms 3, 4, and 
5 with respect to the undersigneds holdings of and transactions in 
securities issued by the Company, unless earlier revoked by the 
undersigned in a signed writing delivered to the Company and the 
foregoing attorneys-in-fact.
       
       IN WITNESS WHEREOF, the undersigned has caused this Power of 
Attorney to be executed as of this 1 day of September, 2017.


Signature:	/s/ Bradley P. Morgan

Print Name:	Bradley P. Morgan